Mobocertinib added in NICE guidelines
NICE guidelines have added the guidance on mobocertinib to the systemic anti-cancer therapy treatment pathways for advanced non-small-cell lung cancer.
They would like your feedback on how the treatment pathways present content from different sources (NICE technology appraisal guidance, guideline recommendations, and expert input). To comment, go to the link below on systemic anti-cancer therapy for advanced non-small-cell lung cancer and fill in the pop-up survey.
Recent Posts
Navigating Economic Resilience Through Life Sciences Investment
Navigating a Leaderless Global Economy Through Life Sciences Investment
In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
EU Medicine Authorizations 2025: A Year of Innovation
Advancements in EU Medicine Authorizations for 2025
In 2025, the European Medicines Agency (EMA) recommended 104 medicines for marketing authorisati...
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children
FDA Labeling Mandate on Febrile Seizure Risks
In a significant update to vaccine safety protocols, the U.S. Food and Drug Administration (FDA) has required pediatric influenza vaccines to include warnings about an elevated risk of febri...